Algert Global LLC Acquires 46,630 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Algert Global LLC boosted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 27.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 213,465 shares of the company’s stock after buying an additional 46,630 shares during the quarter. Algert Global LLC owned about 0.15% of Vir Biotechnology worth $1,599,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of VIR. Vanguard Group Inc. lifted its stake in shares of Vir Biotechnology by 0.6% in the first quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock worth $125,362,000 after buying an additional 78,216 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth about $1,780,000. Point72 Hong Kong Ltd grew its holdings in Vir Biotechnology by 180.6% in the 2nd quarter. Point72 Hong Kong Ltd now owns 19,572 shares of the company’s stock valued at $174,000 after buying an additional 12,598 shares during the last quarter. Millennium Management LLC increased its position in Vir Biotechnology by 94.6% in the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after buying an additional 606,804 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Vir Biotechnology by 116.6% during the first quarter. Russell Investments Group Ltd. now owns 25,971 shares of the company’s stock worth $263,000 after buying an additional 13,981 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the sale, the director now owns 11,616 shares of the company’s stock, valued at $90,604.80. This represents a 51.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders sold 15,940 shares of company stock worth $127,410. 15.60% of the stock is currently owned by insiders.

Vir Biotechnology Price Performance

Vir Biotechnology stock opened at $7.86 on Thursday. Vir Biotechnology, Inc. has a one year low of $6.56 and a one year high of $13.09. The business has a 50 day simple moving average of $7.89 and a 200 day simple moving average of $8.82. The company has a market capitalization of $1.08 billion, a PE ratio of -2.01 and a beta of 0.46.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The firm had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company’s revenue for the quarter was down 9.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.22) earnings per share. Equities analysts anticipate that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on VIR shares. Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Barclays decreased their price objective on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Vir Biotechnology presently has an average rating of “Moderate Buy” and an average price target of $36.40.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).